Alendronate treatment in osteogenesis imperfecta


MADENCİ E.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, vol.12, no.2, pp.53-56, 2006 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 2
  • Publication Date: 2006
  • Doi Number: 10.1097/01.rhu.0000208490.22492.09
  • Journal Name: JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.53-56

Abstract

Aims: Osteogenesis imperfecta (01) is a chronic, disabling condition characterized by bone fragility resulting from defective production of type I collagen. Pamidronate therapy is the most extensively studied treatment and has proved beneficial. Our objective was to evaluate the effect of alendronate, a more potent bisphosphonate than pamidronate, in OI.